TET1 and head and neck squamous cell carcinoma: In the TCGA cohort of HNSCC, TET1, TET2 and TET3 mutations were identified in 9 of 510 patients (1.8%), 8 patients (1.6%) and 8 patients (1.6%), respectively [36].